Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gemcitabine | DNA replication | DNA replication | 0.0255 | 0.1767 | 1.3221 | -0.1534 | 0.1060 | 0.2747 | -0.1430 | 0.1441 | 0.3026 | 0.5558 | 1.2204 | 2.6334 | 0.3723 | 0.5392 | 0.7460 | 0.0153 | 0.0741 | 0.2614 | |
| Cisplatin | DNA cross-linker | DNA cross-linker | 4.4823 | 11.6380 | 25.2438 | -0.8850 | -0.6449 | -0.2565 | -0.9047 | -0.5931 | -0.2921 | 1.0217 | 1.3698 | 2.2177 | 0.2715 | 0.3752 | 0.4391 | 8.7984 | 21.1543 | 38.4325 | |
| Oxaliplatin | DNA cross-linker | DNA cross-linker | 3.2681 | 4.9333 | 12.0662 | -0.9391 | -0.8084 | -0.7104 | -1.0000 | -1.0000 | -0.9516 | 0.6228 | 0.7486 | 1.0057 | 0.4005 | 0.5419 | 0.5768 | 14.7918 | 22.6957 | 42.6124 | |
| Carboplatin | DNA cross-linker | DNA cross-linker | 30.4522 | 52.4276 | 91.0569 | -0.9081 | -0.7672 | -0.5844 | -0.9460 | -0.8644 | -0.7390 | 1.2433 | 1.6402 | 2.1619 | 0.2714 | 0.3706 | 0.4859 | 52.1319 | 91.7409 | 100.0000 | |
| TCS 2312 | CHK1 | CHK | 0.3474 | 0.6156 | 0.9604 | -0.8358 | -0.6163 | -0.3941 | -0.8432 | -0.6104 | -0.3951 | 1.4081 | 2.0751 | 2.9131 | 0.3572 | 0.4368 | 0.5565 | 0.6031 | 1.0589 | 1.5099 | |
| Purvalanol A | CDK1 | CDK | 25.2896 | 54.7310 | 100.0000 | 0.0757 | 0.5333 | 0.7416 | -0.0675 | 0.5068 | 0.7450 | 1.0817 | 2.5000 | 4.2404 | 0.0335 | 0.0774 | 0.1767 | 18.1854 | 35.4887 | 52.3768 | |
| Fascaplysin | CDK4 | CDK | 0.1734 | 0.2805 | 0.3987 | -0.9809 | -0.9546 | -0.8701 | -0.9898 | -0.9538 | -0.8570 | 1.9348 | 2.3235 | 2.8230 | 0.5843 | 0.6643 | 0.7626 | 0.3281 | 0.4110 | 0.6267 | |
| NU6102 | CDK1/2 | CDK | 12.2242 | 17.3275 | 31.6450 | -0.7759 | -0.4783 | -0.1439 | -1.0000 | -0.9972 | -0.6085 | 1.3221 | 1.8051 | 3.6950 | 0.1178 | 0.1554 | 0.2440 | 20.2928 | 27.4520 | 55.8294 | |
| Olomoucine II | CDK1 | CDK | 3.7444 | 6.0358 | 7.3956 | -0.7023 | -0.3927 | -0.1441 | -0.7230 | -0.4357 | -0.1137 | 1.4260 | 2.7083 | 4.7257 | 0.2563 | 0.3202 | 0.3981 | 5.9885 | 7.0813 | 8.6384 | |
| NSC 663284 | CDC25 | CDC | 1.6689 | 2.2519 | 3.0742 | -0.9668 | -0.9336 | -0.8607 | -0.9846 | -0.9413 | -0.8554 | 1.8405 | 2.5456 | 4.2988 | 0.5484 | 0.5805 | 0.6318 | 2.2603 | 3.4718 | 5.7633 | |
| GSK1070916 | AURK | AURK | 0.6046 | 3.0981 | 6.6549 | -0.8474 | -0.6391 | -0.3610 | -1.0000 | -1.0000 | -0.9999 | 0.6499 | 0.9902 | 1.5949 | 0.2113 | 0.2924 | 0.4314 | 3.5405 | 8.2453 | 15.6107 | |
| Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.9523 | 4.3787 | 11.8540 | -0.5661 | -0.3376 | -0.0359 | -1.0000 | -1.0000 | -0.4350 | 0.4858 | 0.8218 | 1.3502 | 0.1794 | 0.3014 | 0.3656 | 4.7346 | 16.5294 | 34.8041 | |
| ZM-447439 | AURK | AURK | 3.5193 | 19.1991 | 100.0000 | -0.0403 | 0.4141 | 0.5578 | -0.1176 | 0.3301 | 0.5652 | 0.5578 | 1.0337 | 2.9596 | 0.1428 | 0.2012 | 0.3024 | 0.6732 | 2.5837 | 16.4745 | |
| Sigma A6730 | AKT | AKT | 2.0327 | 6.5660 | 11.2198 | -0.9178 | -0.8320 | -0.6777 | -1.0000 | -1.0000 | -0.9546 | 0.9310 | 1.3794 | 2.0044 | 0.2439 | 0.2875 | 0.4042 | 6.3004 | 13.6236 | 19.0461 | |
| Triciribine | AKT | AKT | 0.1497 | 1.0069 | 10.2321 | -0.2208 | 0.0730 | 0.3595 | -0.6783 | -0.3270 | 0.0049 | 0.3693 | 0.5173 | 0.9769 | 0.1961 | 0.3180 | 0.4712 | 0.2958 | 1.3169 | 18.2553 |